

REMARKS

Claims 127 and 129 are pending.

A. Regarding double patenting

The Action continues to reject claims 127 and 129 under the judicially created doctrine of obviousness-type double patenting as allegedly unpatentable over claim 1 of U.S Pat. No. 6,426,209 B1 (the '209 patent). Applicants respectfully traverse the rejection.

Attached are terminal disclaimers from (A) InSight Strategy and Marketing Ltd. ("InSight"); and (B) Hadasit Medical Research Services and Development Ltd., the co-owners of the subject application.

Accordingly, Applicants respectfully request that this rejection be withdrawn.

CONCLUSION

All of the issues raised in the Office Action have been addressed and are believed to have been overcome. Therefore Applicants respectfully request a Notice of Allowance to this effect.

Respectfully submitted,



Martin Moynihan,

Registration Number 40,338

Date: March 16, 2009

Enclosure:

- Terminal Disclaimer (regarding U.S Pat. No. 6,426,209 B1)